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Abstract 
As part as of the preformulation studies of new 5'-OH derivatives of zidovudine, 
compounds  2–6,  their  acid dissociation constants,  Differential Scanning 
Calorimetry (DSC) and Thermogravimetry (TG) curves, X-Ray Powder 
diffractograms and aqueous stability are reported. A sensitive technique such 
as differential scanning potentiometry was used to determine the pKa constants 
of the above mentioned compounds. In addition, pKa values were calculated 
from theoretical methods, and no significant differences with those of 
experimental ones were observed. X-Ray Powder Diffractometry data 
demonstrated that compounds 2–4  were  crystalline while 5  and  6  were 
amorphous. DSC analysis indicated that all of them presented an exothermic 
decomposition peak above 150 °C which is accompanied by a weight loss in the 
respective TG curves. The stability of these compounds in aqueous medium at 
different pH values was investigated, using a validated High Performance Liquid 
Chromatography (HPLC) method, which demonstrated to be rapid, selective, 
sensitive, accurate and stability-indicating.  Good recovery, linearity and 
precision were also achieved. For all compounds  the aqueous hydrolysis 
followed a pseudo-first-order kinetics, depending on pH and the union existing 
between AZT and the associate moiety. The hydrolysis was catalyzed by 
hydroxide ion in the 7.4–13.2 pH range, while all compounds exhibited 
pH-independent stability from acidic to neutral media (pHs 1.0–7.4). 480  M. A. Raviolo and M. C. Briñón:   
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Introduction 
Acquired immunodeficiency syndrome (AIDS) results from infection by the retrovirus, 
human immunodeficiency virus (HIV-1) [1]. 3’-Azido-3’-deoxythymidine (zidovudine, 
AZT, 1), the first clinically successful nucleoside analog for the treatment of AIDS, is a 
potent nucleoside reverse transcriptase inhibitor (NRTI) of HIV-1 replication [2], particularly 
when used in combination with other drugs, such as other NRTIs, non-nucleoside reverse 
transcriptase and protease inhibitors [3]. Although nucleoside analogues continue to play a 
prominent role as antiviral agents [4], their therapeutic potential is often hampered by their 
poor biopharmaceutical properties [5]. Therefore, as part of our ongoing efforts to search 
for novel antiviral agents, we developed AZT derivatives with anti HIV activity, modifying 
the 5’-OH position of AZT which could form a reservoir of the drug in different human 
tissues, thus requiring less frequent dosing [6–11]. 
Parameters obtained from preformulation studies are essential to understand the biological 
activity of drugs, by depicting a more accurate picture of the macromolecule-ligand binding 
interaction. Through these studies, it is possible to derive valuable information on different 
properties of drugs [12–14].  Thus, the acid dissociation constant (pKa) is a useful 
physicochemical parameter to evaluate the extent of ionization of functional groups related 
to pH, often of vital significance to understand the pharmacokinetic and pharmacodynamic 
behavior of a drug substance [15]. Possible lack of sharpness of the inflection points of the 
pH-metric titration to establish the pKa of ionizable groups in aqueous solution is the main 
limiting factor in conventional aqueous acid-base potentiometry, which depends on the 
strength and concentration of the sample species as well as on the presence of interfering 
substances. Differential Scanning Potentiometry (DSP) yields areas as analytical 
responses, thereby enhancing its sensitivity for determining weak acids and bases in 
aqueous systems [16, 17]. 
Differential Scanning Calorimetry (DSC), Thermogravimetry (TG) and X-ray Powder 
Diffractometry (XRPD) are suitable and widely used techniques for the characterization of 
the solid state of a substance for preformulation studies, while stability studies are also 
relevant to evaluate promptly any instability during drug discovery and development, to 
determine whether the whole molecule or their degradation products, as occurs with 
prodrug compounds leading to parent drugs, are responsible for the observed activity [18]. 
Thus, the aim of this work was to describe relevant preformulation determinations for 2–6 
[6] (Fig 1), such as their acid dissociation constants (pKa), DSC and TG curves, XRPD 
profiles  and aqueous stability. These studies were performed since they are important 
early requirements for novel compounds in drug research. Previously, we also have 
reported the lipophilicity and liposome permeability of 2–6 [7, 19].   Preformulation Studies of Zidovudine Derivatives: Acid Dissociation Constants, Differential Scanning …481 
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Fig. 1.  Chemical structures of AZT (1) and its derivatives (2–6). 
Results 
pKa Determination 
In the differential scanning potentiometry (DSP) methodology, acid and basic groups 
generate negative and positive areas, respectively [16, 17]. Thus, the NH acidic groups of 
AZT and thymidine were used as reference to validate the DSP, since their pKa values 
had been previously reported [20]. The linear relationship between the amount of titrated 
sample and the resulting area was first investigated for an interval of 0.04–0.16 mmol L
−1; 
0.12 mmol L
−1  was selected as an appropriate concentration for pKa assays by DSP 
(eq. 1), where C represents the mmol L
−1 concentration. 
Eq. 1.  Area = 21.29 (± 3.32) C + 0.26 (± 0.37) 
  r = 0.994; SD = 0.115; n = 6 
Then, using compounds with different pKa values (sulphanilamide = 2.36 and 3.57; 
procaine hydrochloride = 5.20; lidocaine = 7.86; erytromycine = 8.80; p-aminobenzoic acid 
= 9.10 and potassium hydrogen phthalate = 11.05), the regression analysis of their areas 
vs their pKa values was carried out (eq. 2). 
Eq. 2.  Area = 1.08 (± 0.09) pKa - 2.13 (± 0.67) 
r = 0.998; SD = 0.271; n = 7 
Once the experimental areas for thymidine, 1 and 4–6 were obtained, their pKa values 
were calculated using eq. 2 as shown in Figure 2. 
To confirm the values obtained for the aliphatic amines of compounds 5 and 6, predictive 
methods were followed by applying the Taft equation for protonated secondary amines 
(R1R2NH2
+, pKa = 10.59 –  3.23 Σσ*, where σ* is the electronic Taft constant [21]) as 
previously reported for a related compound [22].  Figure 2 also shows the pKa values 
calculated for 5 and 6. 
 482  M. A. Raviolo and M. C. Briñón:   
Sci Pharm. 2011; 79: 479–491 
N
O O H
OH
NH
O
O
Thymidine
pKa: 9.45
a, 9.70
b
N
O O H
N3
NH
O
O
1
pKa: 9.42
a, 9.68
b
N
O O
N3
NH
O
O N
O
4
pKa: 8.61
a
5
pKa: 8.66
a
pKa: 6.52
a, 6.53
c
N
O O
N3
NH
O
O N N H
O
6
pKa: 9.03
a, 9.20
c
N
O O
N3
NH
O
O
O
N
H
N N H
 
Fig. 2.   Thymidine, 1 and 4–6 derivatives with their ionizable groups and pKa values.  
a Experimental values; 
b previously reported experimental values; 
c calculated 
values employing Taft equations. 
DSC and TG data 
The DSC curves of 2 and 4 (Figure 3) exhibited, in the temperature range of 25–150 °C, 
endothermic peaks at 115.8 and 112.8 °C, respectively (extrapolated onset temperature, T 
onset) due to fusion, while those of compounds 5 and 6 showed a small endothermic peak 
corresponding to a glass transition at 35.1 and 42.5 °C, respectively (T onset). Compound 
3 only displayed a DSC exothermic decomposition peak at 215 °C. Compounds 2, 4, 5 and 
6 also presented an exothermic decomposition peak above 150 °C, which is accompanied 
by a weight loss in the respective TG curves (Figure 3). 
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Fig. 3.   DSC (      ) and TG (      ) curves of AZT (1) and their derivatives (2–6). 
X-Ray powder diffractometry (XRPD) 
XRPD analysis provides an accurate identification of crystalline and amorphous solid 
phases. The XRPD patterns of AZT and their derivatives 2–6 are depicted in Figure 4. The 
diffractograms of 1–4 showed various peaks, indicating that they are solid compounds; 
whereas in 5 and 6, the fine and sharp peak profiles disappeared, yielding a broad band, 
typical of an X-ray amorphous solid. 
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Fig. 4.   X-Ray diffraction patterns of AZT (1) and their derivatives (2–6). 
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Aqueous stability 
Stability in buffers of pH values corresponding to gastrointestinal tract (GI) and plasma 
media is important for drug candidates. The pH of GI varies from acidic (pH 1.2) in the 
stomach to basic pH (pH 8.0) in the small and large intestine. Therefore, acceptable 
stability in the pH range along the aqueous GI and plasma media is essential to achieve 
good oral bioavailability. Before determining the kinetics of the compounds assayed, it is 
necessary to validate the analytical method. 
Validation method 
The standard graphs for all compounds were satisfactorily described by least-square linear 
regression. Calibration graphs were constructed using the areas of the chromatographic 
peaks (triplicate injections) obtained at eight different concentrations, equally distributed in 
the range from 1 x 10
−6 to 1 x 10
−4 mmol mL
−1 for all compounds. The limits of detection 
(LOD) and quantification (LOQ) for the compounds were calculated with the 3s criterion 
and the 10s criterion  (three and ten times the standard deviation of the lowest 
concentration solution included in the calibration divided by the slope of the calibration 
curve) using a series of 10 solutions containing a low concentration of each compound. 
Precision, defined as the relative standard deviation (RSD %), was determined by intra- 
and inter-day assays at a medium concentration, according to the calibration graph ranges 
(Table 1). The intra-day precision was calculated by measuring the areas of the peaks 
obtained from 10 injections of a test solution on the same day. The inter-day analysis 
involved the average of ten measurements of intra-day values calculated during ten days 
over a 3-month period at the same concentrations by different analysts and in different 
equipment. 
Table 1 shows the slopes, intercepts, regression coefficients (r) of the calibration graphs, 
LOD and LOQ, as well as the intra-  and inter-day precision (RSD %)  parameters. As 
described in this table, satisfactory regression coefficients (r ≈ 0.999) for the calibration 
graphs and the percentage of the RSD were obtained. 
Tab. 1.   Parameters of the calibration graphs: slope ±SD, intercept ±SD, regression 
coefficient (r), limit of detection (LOD, mmol mL
−1), quantification (LOQ, mmol 
mL
−1) and intra- and inter-day precision (RSD %) for the compounds studied  
(1–6). 
Compound 
 
Slope (10
7) 
±SD (10
5) 
Intercept 
±SD 
r 
 
LOD 
(10
−7) 
LOQ 
(10
−7) 
RSD % 
Intra  Inter 
AZT, 1  2.6 ± (8.6)  25.5 ± (28.6)  0.999  3.0  3.1  0.42  0.45 
AZT-Tos, 2  3.7 ± (2.0)  1.6 ± (4.8)  0.999  0.6  1.0  0.09  0.38 
AZT-Cycl, 3  3.3 ± (6.5)  5.9 ± (31.7)  0.999  2.5  3.0  1.03  1.70 
AZT-Py, 4  2.4 ± (5.6)  −2.7 ± (27.3)  0.999  2.1  2.2  0.17  0.36 
AZT-Pyp, 5  5.3 ± (2.5)  10.2 ± (16.3)  0.999  8.3  9.8  0.95  1.36 
AZT-Ethy, 6  1.1 ± (6.7)  −1.6 ± (44.1)  0.998  7.7  8.9  0.21  0.79 
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Identification of Degradation Products 
The stress kinetic for degradation of 2–6 was evaluated at 50, 70 and 90 °C in aqueous 
media at different pH buffers (1.0, 2.6, 7.4, 9.4 and 13.2). In all cases, identification of 
each intact compound and AZT (the main degradation product) was performed using 
HPLC, by comparing their HPLC retention times (tR) with those of authentic samples. 
Three solvent systems, A, B and C, were used to obtain an optimal separation of the 
compound peaks. For solvent system A, tR peaks appear at 3.0 min for 1, 11.0 min for 2, 
2.0 min for 3 and 10.8 min for 4; for solvent system B, tR peaks appear at 4 min for 1, 4.8 
min for 5 and 5.2 min for 6; and for solvent system C, tR peaks appear at 5.0 min for 1 and 
3.6  min for 3. Hence, good peak separations were obtained enabling identification of 
compounds 2–6. As an example, Figure 5 shows the HPLC chromatograms of AZT-Tos 
(2) and their degradation compounds (AZT, 1 and AZT-Cycl, 3), using solvent system A. 
The chromatograms correspond to samples of different times: 0, 40 and 90 min of the test 
at pH 9.4. 
Min
0 2 4 6 8 10 12
m
A
U
0
50
100
150
200
250
0 min 
40 min
90 min
AZT-Tos
AZT
AZT-Cycl
 
Fig. 5.   Chromatograms corresponding to AZT-Tos and their degradation products (AZT 
and AZT-Cycl), using system A as eluting mobile phase. The chromatograms 
correspond to samples at different times, 0, 40 and 90 min at pH 9.4. 
Stability Studies 
The aqueous stability studies for 2–6 were carried out at different pH media (1.0, 7.4, 9.4 
and 13.2) to determine whether the whole molecule or its degradation products were 
responsible for the anti-HIV activity observed [6]. These studies were carried out at 60 °C, 
and showed a linear relationship between the logarithmic concentration of the intact drug 
and the storage time, thereby indicating a pseudo-first-order degradation kinetics at the 
pHs analyzed. Table 2 lists the pH media, experimental rate constants (kobs, when it could 
be determined) and their corresponding half-life times (t½). 
As expected, analysis of Table 2 shows that AZT proved to be stable at the studied pH 
media. All AZT derivatives, except 2, led to AZT as the degradation product, while 2 at pHs 
7.4 and 9.4 yielded 3  as the degradation product. This is not surprising since 3  was 
obtained from 2 in an alkaline environment [6] resulting in greater instability for increasing 
pH. On the other hand, 3 proved to be more stable than 2 at pH 7.4. 486  M. A. Raviolo and M. C. Briñón:   
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Tab. 2.   Aqueous stability of AZT (1) and their derivatives (2–6) for different pHs at 
60 °C.  
Compound  pH medium 
1.0  7.4  9.4  13.2 
AZT, 1  Stable
a  Stable
a  Stable
a  Stable
a 
AZT-Tos, 2  Stable
a  0.94
b;725.4
c  14.9
b; 46.5
c  15.1
b; 45.9
c 
AZT-Cycl, 3  5.43
b; 128
c  0.15
b; 4750
c  5.58
b; 124.2
c  Unstable
d 
AZT-Py, 4  Stable
a  Stable
a  Stable
a  1.04
b; 674
c 
AZT-Pyp, 5  Stable
a  Stable
a  Stable
a  3.23
b; 238
c 
AZT-Ethy, 6  Stable
a  Stable
a  Stable
a  1.96
b; 389
c 
a Stable: degradation products by HPLC were not observed after 80 h of experiment; 
b Degradation rate constant, kobs (10
−3 min
−1); 
c t½ min. 
dThe determination was not 
possible due to a rapid decomposition. 
 
The 5’-O-carbamate compounds 4-6 showed degradation reactions at an alkaline pH of 
13.2, with kobs values of 1.04 x 10
−3, 3.23 x 10
−3 and 1.96 x 10
−3 min
−1, respectively due to 
a base catalysis with a decreasing stability of 4 > 6 > 5. Similar results were observed by 
Norberto et al. for related compounds at different pH values [23]. 
Discussion 
The validation of DSP technique for determining the pKa of 2–6 was carried out using two 
reference compounds (AZT and thymidine). Then the pKa of the NH group of the 
pyrimidinic base of 4 and 5 was calculated. Similar values to that of AZT were obtained, 
which indicated that DSP is adequate for determining pKa values for this type of 
compounds. 
The acid dissociation constants for aliphatic amines of 5 and 6 were also determined, with 
a pKa 9.03 for the amine moiety of 6  showing a higher basicity than that of the 
corresponding amine group of 5 (pKa 6.52). This occurred since this NH group in 6 was far 
from the carbamate group and expected to influence on its ionization. The pKa values 
calculated from Taft method [21] or the amine groups of 5 (pKa 6.53) and 6 (pKa 9.20) 
showed a good correlation with those of the experimental ones (Figure 2). 
Under the crystallization conditions used, compounds 2  (from EtOH), 3  [from 
EtOAc/(CH3)2CO] and 4  [from (CH3)2CO/MeOH] crystallized while 5  and  6  [from 
(CH3)2CO/MeOH] did not. On the other hand, DSC and TG data demonstrated that 
compounds  2  (115.8 °C) and 4  (112.8 °C) showed sharp melting peaks, typical of 
crystalline solids, and compounds 5 and 6 exhibited glass transitions at 35.1 and 42.5 °C, 
respectively, discarding the possibility that they crystallized as microcrystalline solids. 
Regarding the crystallization properties of the studied compounds, it is interesting to note 
that a similar behavior was observed for other AZT esters [11,24], i.e. under similar 
crystallization conditions to those used with 2–6, some crystallized and others not. 
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In aqueous stability studies, all derivatives decomposed to give AZT, the parent drug, 
following pseudo first-order kinetics. It should be noted that compound 2  at neutral or 
alkaline pH was first degraded to 3, before giving AZT in a second step. Derivatives 2 and 
3  demonstrated different stabilities depending on the pH environment, while 
5’-O-carbamates 4–6 only decomposed in a strong alkaline media (pH 13.2). Previously, 
we reported that compound 2 and carbamates 4–6 were stable in rat plasma since they 
were able to display conformations that did not allow their access to the catalytic cavity of 
the enzyme able to hydrolyze them [6]. The carbamate derivatives have demonstrated a 
strong bond between AZT and the associated moieties, preventing hydrolysis and parent 
compound regeneration. For this reason, compounds 2, 4–6 could not act as prodrugs, as 
they lacked the necessary activity found in previous in vitro studies [6].  The aqueous 
stability of the cyclic derivative 3 was different from that of the carbamates. Thus, it could 
be degraded in highly acidic (pH 1, t1/2 = 128 min) or alkaline (pH 9.4, t1/2 = 124.2 min) 
media, thereby obtaining high stability in the neutral medium (pH 7.4, t1/2 = 4750 min). 
Moreover, this compound showed stability in rat plasma for 30 h of incubation at 37 °C, 
which implied that it was also acting as a drug, since this derivative was found to have 
anti-HIV activity and no cytotoxicity [6]. 
Experimental 
Materials 
Methanol (MeOH) HPLC grade, was purchased from Baker Co. Dimethylsulfoxide (DMSO) 
and tetrahydrofurane (THF), both of analytical grade, were provided by Cicarelli Co 
(Buenos Aires, Argentina). The water used in HPLC analyses and in all studies was of 
Milli-Q grade, and mobile phases were filtered through Millipore
 filters Type FH (4.5 µm) 
and degassed under vacuum. All other chemicals and solvents were of analytical grade. 
AZT was generously supplied by Filaxis (Buenos Aires, Argentina). Compounds 2–6 were 
prepared as reported [6]. 
pKa - Differential Scanning Potentiometry (DSP) 
A conventional pH-meter (GLP 21, Crison Instrument) with an Ag/AgCl-reference electrode 
was used. NaOH was added at 0.1 mL increments, with its corresponding pH value 
recorded from the average of two sample determinations using DMSO as the cosolvent 
(2.5 %) at 25 °C. The areas were calculated using the Origin 7 program. For the reference 
graph, an aliquot of 10 mL of HCl (0.1 mol L
−1) and 0.5 mL of DMSO was titrated with 
NaOH (0.1 mol L
−1); for the sample graphs, aliquots (10 mL) of HCl (0.1 mol L
−1), 0.5 mL 
DMSO and 0.12 mmol for each compound were titrated with NaOH (0.1 mol L
−1). The 
volume of each solution was completed to 20 mL with Milli-Q water before titration. 
Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TG) and 
X-Ray Powder Diffractometry (XRPD) 
DSC measurements were carried out using a 2920 modulated DSC (TA Instrument). The 
temperature axis and the cell constant of the DSC were calibrated with indium. Weighed 
samples (1.5–3 mg, C-33 Microbalance, Cahan) were scanned in covered aluminium (Al) 
pans under a dynamic dry nitrogen atmosphere (50 mL min
−1) starting at 25 °C and raising 
the temperature in 5 °C steps until reaching 300 °C. TG measurements were performed 
with a TA Instrument Hi-res TG 2950 (TA Instrument). Samples (1.5–3 mg) were weighed 488  M. A. Raviolo and M. C. Briñón:   
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in Al pans, starting at 25 °C  and raising the temperature in 5 °C  steps until reaching 
300 °C, under a dynamic dry nitrogen atmosphere (50 mL min
−1). The Universal Analysis 
Version 2.5H software was used for both measurements. The  XRPD patterns were 
determined at around 20 °C using a diffractometer (Miniflex 2000, Rigaku), with CuKα 
radiation (λ= 1.5418 Å) being obtained by Ni-filtration. Each sample was packed into an Al 
holder in the range of 5-50 (2Θ). 
Stability studies 
The aqueous stability of AZT and their derivatives 2–6  was examined at different pH 
values: pH 1.0 (hydrochloric acid-potassium chloride); pH 2.6 (citric acid-sodium 
phosphate monobasic); pH 7.4 (sodium phosphate dibasic); pH 9.4 (sodium hydrogen 
carbonate-sodium  hydroxide) and pH 13.2 (potassium chloride-sodium hydroxide). The 
buffer concentrations were 0.1 mol L
−1  and the ionic strength (µ) of the buffers was 
adjusted to 0.1 with calculated amount of sodium chloride (NaCl). All buffer solutions were 
prepared with Milli Q water. The pH of each solution was determined using a GLP 21 
(Crison Instruments) pHmeter. Stock solutions (5 x 10
−5 mol mL
−1) of each compound were 
prepared in DMSO prior to use, with 10 µL of the stock solution being added to 990 μL of 
buffer, and the vials placed in a water bath at 60 °C during all the experiment. Each vial 
was withdrawn at predetermined time intervals, and immediately stored at −18 °C until 
being used. For their analysis, the samples were left to defrost, and the aliquots of 100 μL 
were sampled and added to 400 μL of MeOH at 25 °C. Then, the solution was analyzed by 
HPLC to determine the rate of disappearance of each compound. 
HPLC analysis 
Samples were analyzed using an HPLC system Agilent
®  1100 equipped with 
Phenomenex
® column: Hypersil ODS 5 μ particle diameter (4.6 x 250 mm). Detection was 
carried out with an UV detector at λ = 267 nm, using the following three solvent systems 
as mobile phases with a flow rate of 1 mL min
−1 at 35 °C: A); 50% phosphate buffer (pH 
7.5, 0.02 mol L
−1), 50% MeOH and 2% THF; B) 60% phosphate buffer (pH 7.5, 0.02 mol 
L
−1), 40% MeOH and 2% THF; and; C) 65% phosphate buffer (pH 7.5, 0.02 mol L
−1), 35% 
MeOH and 2% THF to obtain an adequate peak separation. 
Conclusions 
Different techniques were employed to establish preformulation parameters of a series of 
AZT derivatives. Thus, the acid-basic behavior of ionizable groups was determined to 
identify the pKa of each analogue as well as most relevant DSC, TG and XRPD 
characteristic as well as the stability of 2–6 in a wide pH range were also assayed. From 
an integral analysis of the studies mentioned above and those previously reported (anti 
HIV activity, cytotoxicity and lipophilicity), we can conclude that compound 3  is an 
excellent candidate for offering a  wide therapeutic potential, and consequently merits 
further investigation for an integral analysis performing complementary biopharmaceutical 
studies. 
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